PPARδ agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-25. Numbers and descriptions here follow the published literature rather than marketing material.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
=== Peak phase === The positive feedback of the rising phase slows and comes to a halt as the sodium ion channels become maximally open. At the peak of the action potential, the sodium permeability is maximized and the membrane voltage Vm is nearly equal to the sodium equilibrium voltage ENa. However, the same raised voltage that opened the sodium channels initially also slowly shuts them off, by closing their pores; the sodium channels become inactivated. This lowers the membrane's permeability to sodium relative to potassium, driving the membrane voltage back towards the resting value. At the same time, the raised voltage opens voltage-sensitive potassium channels; the increase in the membrane's potassium permeability drives Vm towards EK. Combined, these changes in sodium and potassium permeability cause Vm to drop quickly, repolarizing the membrane and producing the "falling phase" of the action potential.
Artifacts found outside their original context (ex situ), often due to natural disturbances or amateur excavations, have less interpretive value, but may provide clues about the spatial distribution and typological characteristics of unexcavated in situ deposits, guiding future excavation efforts. The Convention on the Protection of the Underwater Cultural Heritage sets mandatory guidelines for signatory states regarding the treatment of underwater shipwrecks. One of its main principles is that in situ preservation is the preferred approach. This policy is based on the unique conditions of underwater environments, where low oxygen levels and stable temperatures help preserve artifacts over long periods. Removing artifacts from these conditions and exposing them to the atmosphere often accelerates deterioration, particularly the oxidation of iron-based materials. In mortuary archaeology, in situ documentation involves systematically recording and cataloging human remains in their original depositional positions. These remains are often embedded in complex matrices of sediment, clothing, and associated artifacts. Excavating mass graves presents additional challenges, as they may contain hundreds of individuals. Before identifying individuals or determining causes of death, archaeologists must carefully document spatial relationships and contextual details to preserve forensic and historical information.
=== Marijuana === Similar to alcohol, marijuana is absorbed into the bloodstream and crosses the blood brain barrier. Notably, the THC released from marijuana binds to the CB-1 cannabinoid receptors, inducing various effects. These effects encompass mood changes, altered perception of time, and heightened sensitivity, among others.
Yusuf Shihab and Bashir Shihab II were the only Maronite rulers of the Emirate of Mount Lebanon. The Shihab family allied with Muhammad Ali of Egypt during his occupation of Syria, but was deposed in 1840 when the Egyptians were driven out by an Ottoman-European alliance, leading soon after to the dissolution of the Shihab emirate. Despite losing territorial control, the family remains influential in modern Lebanon, with some members having reached high political office. The Khazens opposed the creation of the "Double Qaimaqmate" in Mount Lebanon in the 1840s, which divided Mount Lebanon into Druze and Christian-run sectors, and were incensed at the appointment of a sheikh from the mixed Druze-Christian Abu'l-Lama family as the qaimaqam (deputy governor) of the Maronite section of the Qaimaqamate. The Khazens feared that such an appointment would formally subordinate them to the Abu'l-Lama sheikhs. Several Khazen family members became destitute in the 1830s and 1840s and Khazen influence over the Maronite Church waned. To compensate for their economic, social and political stagnation, the Khazens increased their pressure on the peasants of Kisrawan in the late 1850s, while also spending extravagantly. The "Druze-Christian alliance" during this century was the major factor enabling the Shehab dynasty to maintain power.
In July 2017, the FDA announced a plan that would reduce the current levels of nicotine permitted in tobacco cigarettes. The proposed regulation, identified as RIN 0910-AI76, titled "Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products," seeks to reduce the nicotine content in cigarettes to approximately 0.7 milligrams per gram of tobacco.
Sources: en.wikipedia.org
== DNA assembly == DNA printing can thus be used to produce DNA parts, which are defined as sequences of DNA that encode a specific biological function (for example, promoters, transcription regulatory sequences or open reading frames). However, because oligonucleotide synthesis typically cannot accurately produce oligonucleotides sequences longer than a few hundred base pairs, DNA assembly methods have to be employed to assemble these parts together to create functional genes, multi-gene circuits or even entire synthetic chromosomes or genomes. Some DNA assembly techniques only define protocols for joining DNA parts, while other techniques also define the rules for the format of DNA parts that are compatible with them. These processes can be scaled up to enable the assembly of entire chromosomes or genomes. In recent years, there has been proliferation in the number of different DNA assembly standards with 14 different assembly standards developed as of 2015, each with their pros and cons. Overall, the development of DNA assembly standards has greatly facilitated the workflow of synthetic biology, aided the exchange of material between research groups and also allowed for the creation of modular and reusable DNA parts. The various DNA assembly methods can be classified into three main categories – endonuclease-mediated assembly, site-specific recombination, and long-overlap-based assembly. Each group of methods has its distinct characteristics and their own advantages and limitations.
Most bat species are polygynous, where males mate with multiple females. Male pipistrelle, noctule, and vampire bats may claim and defend resources that attract females, such as roost sites, and mate with those females. Males unable to claim a site are forced to live on the periphery, where they have less reproductive success. Promiscuity, where both sexes mate with multiple partners, exists in species like the Mexican free-tailed bat and the little brown bat. There appears to be bias towards certain males among females in these bats. In a few species, such as the yellow-winged bat (Lavia frons) and spectral bat, adult males and females form monogamous pairs. Lek mating, where males aggregate and compete for female choice through display, is rare in bats but occurs in the hammerheaded bat. Temperate-living bats typically mate during late summer and autumn, while tropical bats may mate multiple times a year. In hibernating species, males will copulate with females in torpor. Female bats use a variety of strategies to control the timing of pregnancy and birth, to make delivery coincide with maximum food availability and other ecological factors. Females of some species use delayed fertilisation, in which mating occurs in late summer to early autumn, but sperm is stored in the reproductive tract, delaying fertilisation until the following late winter to early spring. Other species exhibit delayed implantation, in which the egg is fertilised after mating but does not experience all its cell divisions until external conditions become favourable.
It references a crossover study in which 113 subjects were each given four different treatments in randomized order: placebo, 10 mg/day escitalopram, 30 mg/day escitalopram, or 400 mg/day moxifloxacin (a positive control known to cause QTc prolongation). At 10 mg/day, escitalopram increased the QTc interval by 4.5 milliseconds (ms). At 30 mg/day, the QTc increased by 10.7 ms. A QTc increase of less than 60 ms is not likely to confer significant risk. The 30 mg/day escitalopram dose induced significantly less QTc prolongation than a therapeutically equivalent 60 mg/day dose of citalopram, which increased the QTc interval by 18.5 ms. More data about the cardiac risk from escitalopram can be found in a large observational study from Sweden that took note of all the medications used by all the patients presenting with TdP, and found the incidence of TdP in escitalopram users to be only 0.7 cases of TdP for every 100,000 patients who took the drug (ages 18–64), and only 4.1 cases of TdP for every 100,000 elderly patients who took the drug (ages 65 and up). Of the 9 antidepressants that were used by patients with TdP, escitalopram ranked 7th by TdP incidence in elderly patients (only venlafaxine and amitriptyline had less risk), and it ranked 5th of 9 by TdP incidence in patients ages 18–64. Antidepressants as a class had a relatively low risk of TdP, and most patients on an antidepressant who experienced TdP were also taking another drug that prolonged QT interval.
== Mechanism of action == The mechanism seems to vary with different organisms and is not well understood. However, pentamidine is suspected to work through various methods of interference of critical functions in DNA, RNA, phospholipid and protein synthesis. Pentamidine binds to adenine-thymine-rich regions of the Trypanosoma parasite DNA, forming a cross-link between two adenines four to five base pairs apart. The drug also inhibits topoisomerase enzymes in the mitochondria of Pneumocystis jirovecii. Similarly, pentamidine inhibits type II topoisomerase in the mitochondria of the Trypanosoma parasite, resulting in a broken and unreadable mitochondrial genome.
=== Biochemical logic === The existence of more than one point of regulation indicates that intermediates between those points enter and leave the glycolysis pathway by other processes. For example, in the first regulated step, hexokinase converts glucose into glucose-6-phosphate. Instead of continuing through the glycolysis pathway, this intermediate can be converted into glucose storage molecules, such as glycogen or starch. The reverse reaction, breaking down, e.g., glycogen, produces mainly glucose-6-phosphate; very little free glucose is formed in the reaction. The glucose-6-phosphate so produced can enter glycolysis after the first control point. In the second regulated step (the third step of glycolysis), phosphofructokinase converts fructose-6-phosphate into fructose-1,6-bisphosphate, which then is converted into glyceraldehyde-3-phosphate and dihydroxyacetone phosphate. The dihydroxyacetone phosphate can be removed from glycolysis by conversion into glycerol-3-phosphate, which can be used to form triglycerides. Conversely, triglycerides can be broken down into fatty acids and glycerol; the latter, in turn, can be converted into dihydroxyacetone phosphate, which can enter glycolysis after the second control point.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.